Serious Adverse Events in Randomized Psychosocial Treatment Studies: Safety or Arbitrary Edicts?

被引:34
|
作者
Petry, Nancy M. [1 ]
Roll, John M. [2 ]
Rounsaville, Bruce J. [3 ,4 ]
Ball, Samuel A. [3 ,4 ]
Stitzer, Maxine [5 ]
Peirce, Jessica M. [5 ]
Blaine, Jack [6 ]
Kirby, Kimberly C. [7 ,8 ]
McCarty, Dennis [9 ]
Carroll, Kathleen M. [3 ,4 ]
机构
[1] Univ Connecticut, Ctr Hlth, Dept Med, Calhoun Cardiol Ctr, Farmington, CT 06030 USA
[2] Washington State Univ, Intercollegiate Coll Nursing, Pullman, WA 99164 USA
[3] Yale Univ, Dept Psychiat, West Haven, CT 06520 USA
[4] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA
[5] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD 21218 USA
[6] Natl Inst Drug Abuse, Rockville, MD USA
[7] Treatment Res Inst, Philadelphia, PA USA
[8] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA
[9] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA
关键词
human subjects protection; serious adverse events; psychosocial treatments; good clinical practice; participant safety;
D O I
10.1037/a0013679
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Human subjects protection policies developed for pharmaceutical trials are now being widely applied to psychosocial intervention studies. This study examined occurrences of serious adverse events (SAEs) reported in multicenter psychosocial trials, of the National Institute on Drug Abuse Clinical Trials Network. Substance-abusing participants (N = 1.687) were randomized to standard care or standard care plus either contingency management or motivational enhancement. Twelve percent of participants experienced I or more SAEs during the 27.198 person-weeks of follow-up. Of the 260 SAEs recorded. none were judged by the data safety monitoring board to be study related, and there were no significant differences between experimental and control conditions in SAE incidence rates. These data underscore the need to reconsider the rationale behind, and appropriate methods for. monitoring safety during psychosocial therapy trials.
引用
收藏
页码:1076 / 1082
页数:7
相关论文
共 50 条
  • [21] Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients (vol 6, 101, 2018)
    Zhao, Bin
    Zhao, Hong
    Zhao, Jiaxin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [22] The ability of animal studies to detect serious post marketing adverse events is limited
    van Meer, Peter J. K.
    Kooijman, Marlous
    Gispen-de Wied, Christine C.
    Moors, Ellen H. M.
    Schellekens, Huub
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2012, 64 (03) : 345 - 349
  • [23] A nationwide survey on serious adverse events in healthy volunteer studies in Japan.
    Kumagai, Y
    Fukazawa, I
    Momma, T
    Iijima, H
    Takayanagi, H
    Takemoto, N
    Kikuchi, Y
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P71 - P71
  • [24] POOLED SAFETY ANALYSIS OF ADJUDICATED SERIOUS ADVERSE EVENTS WITH THE COMBINATION OF TIOTROPIUM plus OLODATEROL
    Buhl, R.
    Tetzlaff, K.
    Korducki, L.
    Vogelmeier, C.
    McGarvey, L.
    THORAX, 2015, 70 : A140 - A140
  • [25] Investigating Causes of Serious Adverse Events in Patients with Dementia in the MIND at Home Studies
    Carvalho, L.
    Johnston, D.
    Black, B.
    Reuland, M.
    Lyketsos, C.
    Samus, Q.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2017, 65 : S105 - S105
  • [26] Predicting serious adverse events or a safety net - Rethinking the role of early warning scores
    Haegdorens, Filip
    RESUSCITATION PLUS, 2024, 17
  • [27] Safety of human albumin - serious adverse events reported worldwide in 1998-2000
    Vincent, JL
    Wilkes, MM
    Navickis, RJ
    BRITISH JOURNAL OF ANAESTHESIA, 2003, 91 (05) : 625 - 630
  • [28] The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
    Hou, Helei
    Sun, Dantong
    Liu, Kewei
    Jiang, Man
    Liu, Dong
    Zhu, Jingjuan
    Zhou, Na
    Cong, Jing
    Zhang, Xiaochun
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 4109 - 4118
  • [29] Patient safety in home hemodialysis: Quality assurance and serious adverse events in the home setting
    Pauly, Robert P.
    Eastwood, Deborah O.
    Marshall, Mark R.
    HEMODIALYSIS INTERNATIONAL, 2015, 19 : S59 - S70
  • [30] Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events
    Cates, C. J.
    Lasserson, T. J.
    Jaeschke, R.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (03):